Wednesday, April 11, 2018 5:22:43 PM
https://www.reuters.com/article/us-johnson-johnson-divestiture/johnson-johnson-nears-diabetes-device-exit-with-2-1-billion-lifescan-sale-idUSKCN1GS1G0
https://ih.advfn.com/news/amp/77047270?pid=nmona&article=77047270&__twitter_impression=true
J&J has till mid June to accept the offer which can be extended till the end of the year of 2018 worse case scenario.
Now if I was J&J of course I would settle with DECN for up to $500M in order to be able to the sell the division to get over $2B. Business 101.
DECN chart tells the story!
https://www.stockscores.com/charts/charts/?ticker=Decn
Everything is IMHO. Do your own DD. I don't make you push buttons. You do. Glad I could clear that up for you.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM